Nasal Spray Medicine to Prevent Depression After Childbirth
Part of Mental health, Women’s health & pregnancy clinical trials.
This study tests whether a nasal spray containing two medications (esketamine and dexmedetomidine) can help prevent postpartum depression in pregnant women who show early signs of depression. Postpartum depression is common and can be serious, so this trial explores a new way to treat it right around the time of delivery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be pregnant and preparing to give birth
- You must be 18 years or older
- You must have some symptoms of depression during pregnancy (scored on a simple questionnaire)
- You cannot have serious pregnancy complications like severe high blood pressure or placental problems
- You cannot have a heart condition that prevents you from taking these medications
- Your nasal passages must be clear and healthy (no severe allergies, polyps, or congestion)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a dexmedetomidine nasal spray given during labor can help prevent postpartum depression after childbirth. If you are having a planned vaginal delivery with epidural pain relief, you may be eligible.
This study tests whether esketamine, a nasal spray for depression, can help adults whose depression has not improved with at least two other antidepressants. Participants continue their current treatment while receiving esketamine.
This study tests esketamine nasal spray versus a placebo in adults with depression that has not improved after trying at least two other antidepressants. It aims to see if the spray can help when standard pills have not worked.
This study tests esketamine nasal spray (a fast-acting antidepressant) for people with treatment-resistant depression who haven't gotten better after trying at least two other antidepressants. It looks at how well the spray works in everyday doctor's offices, not just in research clinics.
This study compares the effectiveness of esketamine (Spravato) and another similar drug, ketamine, for adults with major depression that has not improved after trying at least two other antidepressants. It aims to find out which treatment works better.
This trial tests how treatment with esketamine affects metabolism in people with depression. It may help if you have not responded to at least two standard antidepressants.
Hear when a new Depressive Symptoms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.